A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06033261 |
Recruitment Status :
Active, not recruiting
First Posted : September 13, 2023
Last Update Posted : April 3, 2024
|
Sponsor:
ModernaTX, Inc.
Information provided by (Responsible Party):
ModernaTX, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | June 4, 2025 |
Estimated Study Completion Date : | June 4, 2025 |